21.58

3.01% -0.67

After Hours: 21.74 0.16 +0.74%

Biolife Solutions Inc (BLFS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Biolife Solutions Inc stock is traded at $21.58, with a volume of 240.20K. It is down -3.01% in the last 24 hours and down -10.23% over the past month. BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

Previous Close:

$22.25

Open:

$22.36

24h Volume:

240.20K

Relative Volume:

0.68

Market Cap:

$1.04B

Revenue:

$151.91M

Net Income/Loss:

$-46.03M

P/E Ratio:

-21.37

EPS:

-1.01

Net Cash Flow:

$5.65M

1W Performance:

-2.00%

1M Performance:

-10.23%

6M Performance:

-10.31%

1Y Performance:

-18.07%

1-Day Range:

$21.45

$22.36

1-Week Range:

$21.35

$22.99

52-Week Range:

$19.10

$29.62

Biolife Solutions Inc Stock (BLFS) Company Profile

Name

Biolife Solutions Inc

Sector

Healthcare (1112)

Industry

Medical Instruments & Supplies (58)

Phone

(425) 401-1400

Address

3303 MONTE VILLA PARKWAY, BOTHELL, WA

Employee

159

Twitter

@biolifesol

Next Earnings Date

2025-03-03

Latest SEC Filings

BLFS's Discussions on Twitter

Compare BLFS vs ISRG, BDX, ALC, MDLN, RMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BLFS Biolife Solutions Inc	21.58	1.07B	151.91M	-46.03M	5.65M	-1.01
ISRG Intuitive Surgical Inc	478.60	176.19B	10.06B	2.88B	2.49B	7.876
BDX Becton Dickinson Co	177.81	51.41B	21.92B	1.76B	2.63B	6.1223
ALC Alcon Inc	78.55	39.00B	10.19B	1.05B	1.38B	2.1044
MDLN Medline Inc	44.59	37.48B	27.43B	1.27B	1.01B	1.5829
RMD Resmed Inc	245.73	37.82B	5.40B	1.49B	1.78B	10.12

Biolife Solutions Inc Stock (BLFS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-22-25	Resumed	Stephens	Overweight
Sep-30-24	Initiated	H.C. Wainwright	Buy
Apr-04-24	Initiated	Jefferies	Buy
Jul-11-23	Initiated	Craig Hallum	Buy
Apr-25-22	Upgrade	Oppenheimer	Perform → Outperform
Oct-19-21	Initiated	B. Riley Securities	Buy
Oct-15-21	Resumed	Cowen	Outperform
May-14-21	Downgrade	The Benchmark Company	Buy → Hold
Mar-23-21	Upgrade	The Benchmark Company	Hold → Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Sep-22-20	Downgrade	Oppenheimer	Outperform → Perform
Sep-18-20	Initiated	Cowen	Outperform
Aug-11-20	Downgrade	The Benchmark Company	Buy → Hold
Jul-08-20	Reiterated	Maxim Group	Buy
Feb-24-20	Initiated	Lake Street	Buy
Feb-19-20	Initiated	The Benchmark Company	Buy
Feb-06-20	Resumed	B. Riley FBR	Buy
Jan-08-20	Initiated	Stephens	Overweight
Nov-21-19	Initiated	Oppenheimer	Outperform
Jul-22-19	Initiated	H.C. Wainwright	Buy
Nov-10-17	Reiterated	Maxim Group	Buy
Sep-19-17	Reiterated	Maxim Group	Buy
Jul-05-17	Upgrade	Janney	Neutral → Buy
Mar-10-17	Reiterated	Maxim Group	Buy
Jan-19-17	Initiated	Maxim Group	Buy

View All

Biolife Solutions Inc Stock (BLFS) Latest News

03:28 AM

Biolife Solutions signs multi-year supply agreement with Qkine Limited - marketscreener.com

03:28 AM

09:23 AM

BioLife Solutions, Inc. Signs Multi-Year Supply Agreement with Qkine Limited to Expand Its Product Portfolio into the Rapidly Growing Cytokines Market - marketscreener.com

09:23 AM

09:11 AM

BioLife Solutions (BLFS) Secures Supply Deal with Qkine for Key CGT Products - GuruFocus

09:11 AM

08:03 AM

BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market - PR Newswire

08:03 AM

Feb 11, 2026

Aug Big Picture: What are analysts price targets for BioLife Solutions Inc2025 Biggest Moves & Weekly Return Optimization Plans - baoquankhu1.vn

Feb 11, 2026

Bio-Preservation Market to Reach US$ 44.45 Billion by 2035 | Cold Chain Expansion and Cell & Gene Therapy Commercialization Drive Growth Says Astute Analytica - GlobeNewswire Inc.

Feb 11, 2026

Feb 05, 2026

Energy Moves: Is BioLife Solutions Inc being accumulated by smart moneyIPO Watch & Fast Entry High Yield Tips - baoquankhu1.vn

Feb 05, 2026

Options Flow: Does BioLife Solutions Inc offer margin of safetyMarket Sentiment Summary & Consistent Return Strategy Ideas - baoquankhu1.vn

Feb 05, 2026

Feb 03, 2026